The drug, Iovance Biotherapeutics’ Amtagvi, is a tumor-derived autologous T cell immunotherapy that expands a patient’s own T cells to fight the cancer.
The medicine is indicated for unresectable or metastatic melanoma, which is when the cancer cannot be removed surgically or spreads to other body parts. Melanoma is a rare form of skin cancer that accounts for a significant number of cancer-related deaths, the FDA said.
Amtagvi (lifileucel) is the first approved drug for treating solid tumor cancer, Iovance said in a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.